---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-25-000090"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:19:12.278562+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q2 revenue up 22% to $70M; net income $21.5M; raises FY2025 guidance

## Summary
- Total revenue $70.0M (+22% YoY); net product sales $66.6M (+21%); net income $21.5M vs $0.7M in Q2 2024.
- H1 2025 revenue $132.5M (+23%); net income $44.9M vs loss of $10.0M; operating cash flow $45.5M.
- FY2025 total revenue guidance raised to $260-270M (from $250-260M); net product sales $250-260M.
- Board approved $150M increase to share repurchase plan; $138.4M spent on 18.3M shares since Feb 2024.
- Positive Phase 1 data for dual BAFF/APRIL inhibitor aritinercept; plans to start Phase 2 in 2H 2025.

## SEC filing metadata
- accession: 0001600620-25-000090
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000090/0001600620-25-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000090/auph-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-25-000090
- JSON: https://secwatch.observer/filing/0001600620-25-000090.json
- Plain text: https://secwatch.observer/filing/0001600620-25-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.